Within 60 days following submission of the application, the FDA reviews a BLA to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is acce ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Chris Ogden - SVP of Finance and Accounting Sean McCarthy - CEO and Chairman Conference Call Participants Peter Lawson - Barclays Etzer Darout - BMO Capital Markets Mara Goldstein - Mizuho Group Mitchell Kapoor - H.C. Wainwright Joseph Catanzaro - Piper Operator Good day, and thank you for standing by. Welcome to the CytomX Therapeutics Third Quarter 2022 Financial Results Call. [Operato ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Large accelerated filer ☐ Accelerated filer ☒ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 27-3521219 (Stat ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Chau Cheng - Vice President of Investor Relations & Corporate Communications Sean McCarthy - Chief Executive Officer & Chairman Carlos Campoy - Chief Financial Officer Conference Call Participants Kaveri Pohlman - BTIG Etzer Darout - BMO Capital Markets Supawat Thongthip - Mizuho Mitchell Kapoor - H.C. Wainwright Operator Good afternoon, everyone. Thank you for standing by. Welcome to the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Large accelerated filer ☐ Accelerated filer ☒ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 27-3521219 (State or ...

Destroying Cancer. Differently. © 2022 CytomX Therapeutics, Inc. Forward-Looking Statements 2 This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products, preclinical and clinical pipeline and milestones, regulatory objectives, expected payments from a ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Chau Cheng - VP, IR & Corporate Communications Sean McCarthy - CEO & Chairman Amy Peterson - President & COO Carlos Campoy - CFO Conference Call Participants Kaveri Pohlman - BTIG Gavin Scott - JP Morgan Peter Lawson - Barclays Roger Song - Jefferies Boris Peaker - Cowen & Company Mitchell Kapoor - H.C. Wainwright Supawat Thongthip - Mizuho Securities Operator Good afternoon, everyone. Thank ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Large accelerated filer ☐ Accelerated filer ☒ Non-accelerated filer ☐ Smaller reporting company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of Registrant as Spe ...

Destroying Cancer. Differently. © 2022 CytomX Therapeutics, Inc. Forward-Looking Statements 2 This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products, preclinical and clinical pipeline and milestones, regulatory objectives, expected payments from a ...

Call Start: 17:00 January 1, 0000 5:43 PM ET CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2021 Earnings Conference Call March 1, 2022 17:00 ET Company Participants Chau Cheng - Vice President of Investor Relations & Corporate Communications Sean McCarthy - Chairman & Chief Executive Officer Amy Peterson - President & Chief Operating Officer Chris Ogden - Interim Principal Accounting Officer and Vice President of Finance & Accounting Conference Call Participants Gavin Scott - JPMorgan Kaveri Pohlman - BTIG Joe ...